Welcome to our dedicated page for JOHNSON & JOHNSON SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Johnson & Johnson filings document the regulatory record for a New Jersey healthcare company with Innovative Medicine and MedTech operations. Recent 8-K reports cover sales and earnings releases, dividend actions, annual meeting voting results and other material corporate events.
The company’s proxy materials describe board elections, executive compensation votes and shareholder governance matters. Its exchange-registered securities include JNJ common stock and multiple NYSE-listed notes with maturities extending across the company’s long-term debt profile.
Johnson & Johnson has agreed in principle to a comprehensive resolution of remaining ovarian talc litigation with plaintiff firms leading the federal Multi-District Litigation and related state cases. The proposed framework is conditioned on participation from at least 95% of remaining claimants, covering approximately 76,000 ovarian talc claims. It provides per-claim payments under a total $5.5 billion commitment, with a first payment of no more than $3 billion in 2027 and no additional payments due before 2028.
The company links this proposal to a recent MDL court ruling on “specific causation,” after which plaintiffs withdrew certain experts and the court ordered them to show why remaining claims should not be dismissed. Johnson & Johnson states it has already resolved about 95% of filed mesothelioma lawsuits, all state consumer protection claims, and all talc-supplier disputes, and that this agreement, if completed, would efficiently conclude 15 years of talc litigation so it can focus on its Innovative Medicine and MedTech businesses.
Johnson & Johnson reported solid top-line growth for the fiscal second quarter ended June 28, 2026. Sales to customers were $25,310 million, up from $23,743 million, and fiscal six‑month sales were $49,372 million versus $45,636 million, reflecting broad-based increases across Innovative Medicine and MedTech.
Quarterly net earnings were $5,534 million, similar to $5,537 million a year earlier, while six‑month net earnings declined to $10,769 million from $16,536 million, largely against a prior period that included approximately $7.0 billion talc reserve reversal recorded in 2025 and stronger other income. Diluted EPS was $2.27 for the quarter and $4.41 for the six months.
Innovative Medicine generated $16,384 million in second‑quarter sales, led by oncology, neuroscience and strong growth from products such as DARZALEX, CARVYKTI and TREMFYA, while Immunology declined as STELARA faced erosion. MedTech sales were $8,926 million, with growth across cardiovascular, surgery, vision and orthopaedics; the MedTech segment absorbed $0.3 billion in Orthopaedics separation costs in the quarter.
Operating cash flows for the fiscal six months were robust at $11,130 million, supporting $6,358 million in dividends and $4,253 million of share repurchases. Cash and cash equivalents were $20,422 million and total shareholders’ equity was $84,971 million. The present value of the reserve for talc‑related matters was approximately $3.7 billion, about 40% classified as current, with roughly 76,000 U.S. plaintiffs; the company states that while individual periods may be affected, it does not expect these matters, net of accruals, to materially impact its overall financial position.
Strategically, J&J agreed to acquire Firefly Bio, Inc. for $1 billion in cash, expected to close in the fiscal third quarter of 2026, and entered a co‑funding agreement with Royalty Pharma plc for up to $0.5 billion through 2027 to support development of JNJ‑4804, with funding recognized as a reduction of research and development expense as services are performed.
Vanessa Broadhurst, EVP, Global Corp Affairs at Johnson & Johnson, exercised employee stock options for 11,129 and 11,925 shares of Common Stock on July 20, 2026 at exercise prices of $129.5100 and $131.9400 per share, then sold 23,054 shares in transactions described as open market or private at a weighted average price of $251.2660 per share. These options were awarded under the issuer's Long-Term Incentive Plan and become exercisable on the third anniversary of the grant date.
Johnson & Johnson reported second‑quarter 2026 sales of $25.3 billion, up 6.6% from 2025, with Innovative Medicine up 7.8% and MedTech up 4.5%. Net earnings were $5.53 billion and diluted EPS $2.27, compared with $2.29 a year earlier. On a non‑GAAP basis, adjusted net earnings rose to $7.08 billion and adjusted diluted EPS to $2.90, increases of 5.7% and 4.7%.
For the first six months of 2026, sales reached $49.4 billion, up 8.2%, while GAAP net earnings declined to $10.77 billion and EPS to $4.41. Adjusted diluted EPS for the period was $5.60, up 1.3%. Strong operational performance results in the company increasing 2026 guidance, now estimating reported sales of $100.8–$101.4 billion (midpoint $101.1 billion) and adjusted diluted EPS of $11.60–$11.75 (midpoint $11.68). The release also highlights recent approvals and data for products including TREMFYA, CAPLYTA and the Dual Energy THERMOCOOL SMARTTOUCH SF platform, along with broader Innovative Medicine and MedTech pipeline and investment activity.
JOHNSON & JOHNSON executive Kathryn E. Wengel reported an exercise-and-sell transaction in company stock. On June 11, 2026, she exercised 10,000 employee stock options with an exercise price of $115.67 per share and acquired the same number of common shares.
That same day, she sold 10,000 common shares in open-market transactions, with trades executed at prices between $240.14 and $240.19, according to a weighted-average price footnote. After these transactions, she directly owned 114,287.8735 shares of common stock and held 32,965 stock options outstanding.
She also reported indirect holdings of 281 shares through an ESOP position and 90 shares via a 401(k) plan as of the plan’s May 31, 2026 reporting date.
Woods Eugene A. reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Eugene A. Woods received 161.089 Deferred Share Units as a compensation-related award tied to deferral of his cash retainer under the company’s Deferred Fee Plan for Directors. Following this grant, he holds a total of 6,411.959 Deferred Share Units. These units, including dividend equivalent rights, are to be settled in cash upon the end of his board service and mirror the value of one common share each at settlement.
Johnson & Johnson director Daniel E. Pinto received a grant of 134.241 Deferred Share Units on June 9, 2026, tied to a reference price of $232.79 per unit. After this award, he holds 2,320.824 Deferred Share Units.
The units were acquired by deferring his cash retainer under the company’s Amended and Restated Deferred Fee Plan for Directors. These Deferred Share Units are settled in cash when his board service ends and each unit reflects the fair market value of one share of common stock at settlement, including dividend equivalent rights credited over time.
HEWSON MARILLYN A reported acquisition or exercise transactions in this Form 4 filing.
Johnson & Johnson director Marillyn A. Hewson reported receiving 214.786 Deferred Share Units on June 9, 2026 as a grant under the company’s Amended and Restated Deferred Fee Plan for Directors. These units represent deferred cash retainers and are to be settled in cash when her board service ends, bringing her total Deferred Share Units to 15,791.877, including amounts accrued as dividend equivalent rights.